Cargando…

Serum pyrazinamide concentrations in patients with pulmonary tuberculosis

Detalles Bibliográficos
Autores principales:	Lucena, Stefania de Medeiros Araujo, Alberio, Carlos Augusto Abreu, Pinto, Ana Carla Godinho, Vieira, José Luiz Fernandes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Pneumologia e Tisiologia 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733741/ https://www.ncbi.nlm.nih.gov/pubmed/31017228 http://dx.doi.org/10.1590/1806-3713/e20180254

Ejemplares similares

Concentrations of rifampicin in pre-dose samples in patients with pulmonary tuberculosis
por: Uchoa, Breno Kristoffer Beleza, et al.
Publicado: (2019)

Can diabetes mellitus modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis?
por: Fonseca, Adriana Aparecida Durães, et al.
Publicado: (2020)

Influence of sex on the exposure to isoniazid in patients with pulmonary tuberculosis
por: Rivera, Juan Gonzalo Bardalez, et al.
Publicado: (2023)

Ethambutol and pyrazinamide-induced toxic epidermal necrolysis in an immunocompetent adult with tuberculosis
por: Das, Sibes Kumar, et al.
Publicado: (2012)

Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis
por: Werngren, Jim, et al.
Publicado: (2021)

Pyrazinamide resistance in rifampicin discordant tuberculosis
por: Mvelase, Nomonde Ritta, et al.
Publicado: (2022)

Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice
por: Almeida, Deepak V., et al.
Publicado: (2014)

Calcitriol enhances pyrazinamide treatment of murine tuberculosis
por: Zhang, Jing, et al.
Publicado: (2019)

Genetic diversity within Mycobacterium tuberculosis complex impacts on the accuracy of genotypic pyrazinamide drug-susceptibility assay
por: Köser, Claudio U., et al.
Publicado: (2014)

Formulation and Characterization of Pyrazinamide Polymeric Nanoparticles for Pulmonary Tuberculosis: Efficiency for Alveolar Macrophage Targeting
por: Varma, J. N. Ravi, et al.
Publicado: (2015)

Optimization of SABRE for polarization of the tuberculosis drugs pyrazinamide and isoniazid
por: Zeng, Haifeng, et al.
Publicado: (2013)

Host Targeted Activity of Pyrazinamide in Mycobacterium tuberculosis Infection
por: Manca, Claudia, et al.
Publicado: (2013)

Should pyrazinamide be preferred in tuberculosis treatment during pregnancy?
por: Karabay, Oguz, et al.
Publicado: (2013)

Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis
por: Brindle, Richard, et al.
Publicado: (2001)

Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates
por: Huy, Nguyen Quang, et al.
Publicado: (2017)

Mutation in clpC1 encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in Mycobacterium tuberculosis
por: Zhang, Shuo, et al.
Publicado: (2017)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
por: Somoskovi, Akos, et al.
Publicado: (2001)

Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study
por: Miotto, Paolo, et al.
Publicado: (2014)

The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD
por: Sun, Qingan, et al.
Publicado: (2020)

Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide
por: Santucci, Pierre, et al.
Publicado: (2021)

Atypical Genetic Basis of Pyrazinamide Resistance in Monoresistant Mycobacterium tuberculosis
por: Modlin, Samuel J., et al.
Publicado: (2021)

A case report. Rediscovering tuberculostatics drugs: skin rash and pyrazinamide
por: Martínez, Silvia Calpena, et al.
Publicado: (2022)

Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania
por: Juma, Saumu Pazia, et al.
Publicado: (2019)

Pyrazinamide induced thrombocytopenia
por: Kant, Surya, et al.
Publicado: (2010)

Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea.
por: Lee, K. W., et al.
Publicado: (2001)

Cutaneous leukocytoclastic vasculitis due to anti-tuberculosis medications, rifampin and pyrazinamide
por: Kim, Joo-Hee, et al.
Publicado: (2010)

PncAgene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis
por: Untiveros, Katherine Lozano, et al.
Publicado: (2014)

Design, synthesis and biological activity of pyrazinamide derivatives for anti-Mycobacterium tuberculosis
por: Zhou, Shiyang, et al.
Publicado: (2017)

Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis
por: Havlicek, Juliane, et al.
Publicado: (2019)

Pyrazinamide-resistant Tuberculosis Obscured From Common Targeted Molecular Diagnostics
por: Modlin, Samuel J., et al.
Publicado: (2023)

Identification of drug candidates that enhance pyrazinamide activity from a clinical compound library
por: Niu, Hongxia, et al.
Publicado: (2017)

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
por: Tweed, C. D., et al.
Publicado: (2021)

Crystal Structure of the Pyrazinamidase of Mycobacterium tuberculosis: Insights into Natural and Acquired Resistance to Pyrazinamide
por: Petrella, Stéphanie, et al.
Publicado: (2011)

Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis
por: Ahmad, Zahoor, et al.
Publicado: (2012)

Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis
por: Shi, Wanliang, et al.
Publicado: (2014)

Pyrazinamide Resistance, Mycobacterium tuberculosis Lineage and Treatment Outcomes in San Francisco, California
por: Budzik, Jonathan M., et al.
Publicado: (2014)

The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis
por: Kwon, Byoung Soo, et al.
Publicado: (2020)

Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis
por: Whitfield, Michael G., et al.
Publicado: (2022)

No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients
por: Nardotto, Glauco Henrique Balthazar, et al.
Publicado: (2021)

Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis
por: Shi, Dawei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rmaf9nhi53fjd169c1rcc59po7